Charles River Laboratories Change in Accounts Receivable 2010-2025 | CRL
Charles River Laboratories annual/quarterly change in accounts receivable history and growth rate from 2010 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- Charles River Laboratories change in accounts receivable for the quarter ending March 31, 2025 was $-0.029B, a 69.86% increase year-over-year.
- Charles River Laboratories change in accounts receivable for the twelve months ending March 31, 2025 was $0.012B, a 107.36% decline year-over-year.
- Charles River Laboratories annual change in accounts receivable for 2024 was $0.022B, a 164.64% decline from 2023.
- Charles River Laboratories annual change in accounts receivable for 2023 was $-0.033B, a 77.8% decline from 2022.
- Charles River Laboratories annual change in accounts receivable for 2022 was $-0.151B, a 465.35% increase from 2021.
| Charles River Laboratories Annual Change in Accounts Receivable (Millions of US $) |
|
|---|---|
| 2024 | $22 |
| 2023 | $-33 |
| 2022 | $-151 |
| 2021 | $-27 |
| 2020 | $-86 |
| 2019 | $-8 |
| 2018 | $-21 |
| 2017 | $-48 |
| 2016 | $-53 |
| 2015 | $-17 |
| 2014 | $-28 |
| 2013 | $-19 |
| 2012 | $-16 |
| 2011 | $8 |
| 2010 | $-6 |
| 2009 | $21 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $8.198B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $141.127B | 26.17 |
| CVS Health (CVS) | United States | $79.026B | 9.85 |
| Elevance Health (ELV) | United States | $61.847B | 8.32 |
| Cencora (COR) | United States | $55.889B | 19.44 |
| DiDi Global (DIDIY) | China | $23.438B | 24.90 |
| Labcorp Holdings (LH) | United States | $21.888B | 17.27 |
| Natera (NTRA) | United States | $18.376B | 0.00 |
| BioMerieux (BMXMF) | France | $17.068B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $15.072B | 0.00 |
| ICON (ICLR) | Ireland | $13.441B | 12.93 |
| CochLear (CHEOY) | Australia | $13.183B | 0.00 |
| Solventum (SOLV) | United States | $12.410B | 13.14 |
| Medpace Holdings (MEDP) | United States | $11.886B | 31.46 |
| Revvity (RVTY) | United States | $10.400B | 18.04 |
| Viatris (VTRS) | United States | $10.340B | 3.55 |
| Sonic Healthcare (SKHHY) | Australia | $8.699B | 0.00 |
| HealthEquity (HQY) | United States | $7.874B | 34.49 |
| Avantor (AVTR) | United States | $7.741B | 11.36 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.133B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $4.776B | 32.14 |
| Amplifon S.p.A (AMFPF) | Italy | $3.890B | 21.30 |
| BrightSpring Health Services (BTSG) | United States | $3.453B | 26.54 |
| Sotera Health (SHC) | United States | $3.165B | 17.98 |
| GeneDx Holdings (WGS) | United States | $2.899B | 66.84 |
| Surgery Partners (SGRY) | United States | $2.727B | 35.47 |
| Alignment Healthcare (ALHC) | United States | $2.568B | 0.00 |
| Organon (OGN) | United States | $2.535B | 2.69 |
| Concentras Parent (CON) | United States | $2.497B | 14.43 |
| Progyny (PGNY) | United States | $1.928B | 42.43 |
| Premier (PINC) | United States | $1.751B | 13.29 |
| PACS (PACS) | United States | $1.618B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.618B | 32.36 |
| Ardent Health (ARDT) | United States | $1.462B | 6.23 |
| Teladoc Health (TDOC) | United States | $1.226B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.195B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.029B | 7.83 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.882B | 302.50 |
| Agilon Health (AGL) | United States | $0.704B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.683B | 6.40 |
| CareDx (CDNA) | United States | $0.680B | 10.63 |
| Performant Healthcare (PHLT) | United States | $0.598B | 0.00 |
| Embecta (EMBC) | United States | $0.582B | 3.92 |
| Nutex Health (NUTX) | United States | $0.467B | 7.06 |
| Auna S.A (AUNA) | Luxembourg | $0.457B | 10.28 |
| LifeMD (LFMD) | United States | $0.452B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.451B | 0.00 |
| Omada Health (OMDA) | $0.448B | 0.00 | |
| So-Young (SY) | China | $0.438B | 0.00 |
| SBC Medicals (SBC) | United States | $0.433B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.423B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.406B | 0.00 |
| Oncology Institute (TOI) | United States | $0.333B | 0.00 |
| Enhabit (EHAB) | United States | $0.330B | 27.17 |
| Beauty Health (SKIN) | United States | $0.193B | 0.00 |
| DocGo (DCGO) | United States | $0.136B | 22.17 |
| Sera Prognostics (SERA) | United States | $0.102B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.080B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.059B | 0.00 |
| Biodesix (BDSX) | United States | $0.053B | 0.00 |
| KindlyMD (NAKA) | United States | $0.046B | 0.00 |
| ModivCare (MODV) | United States | $0.039B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.038B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.037B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.012B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.012B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.010B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.007B | 0.00 |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |